TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02469428

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Clean air
Description: Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Each subject will be exposed to 0.3 ppb ozone for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
Study: NCT01678963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Squalamine lactate
Description: Ophthalmic solution 0.2%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle control
Description: Ophthalmic solution vehicle control
Study: NCT04369794

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG
Description: 0.1 ml of lyophilized, live and attenuated intradermal BCG vaccine, containing between 2 and 8 x 1.000.000 C.F.U in a single dose

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline in the same volume as the BCG vaccine in a single dose
Study: NCT00729729

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PCA
Description: Placebo tablet, once
Study: NCT00872859

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of Dermal Matrix substitute
Description: Dermal Matrix implanted in post mastectomy pts at time of mastectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of Dermal Matrix substitute
Description: Dermal Matrix implanted in post mastectomy pts at time of mastectomy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of Dermal Matrix substitute
Description: Dermal Matrix implanted in post mastectomy pts at time of mastectomy.
Study: NCT01192581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydroxyethyl starch 130/0.4 and sodium chloride injection
Description: routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1500mg
Study: NCT03520842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study: NCT03773510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin discontinuation
Description: Patients who did not progressed after 6 cycles of trabectedin will stop the treatment and resume drug in case of progression for other 6 cycles.~The treatment will be resumed again at progression for other 6 cycles and this scheme of treatment will be proposed until progression under trabectedin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trabectedin continuation
Description: Patients who did not progressed after 6 cycles of trabectedin will continue the treatment until Progressive Disease or unacceptable toxicity
Study: NCT02981745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT-1530
Description: Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, FL, Diffuse B-cell lymphoma, Mental-cell lymphoma
Study: NCT02961231

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV 2p+1
Description: introduction of PCV in a reduced dosing 2p+1 schedule

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PCV 3p+0
Description: introduction of PCV in a reduced dosing 3p+0 schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV 1p+1
Description: introduction of PCV in a reduced dosing 1p+1 schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV 0p+1
Description: introduction of PCV in a reduced dosing 0p+1 schedule
Study: NCT00431132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol, 10 mcg
Description: Tablets, administered intravaginally twice weekly
Study: NCT02015858

Intervention type: PROCEDURE
Intervention: Chest drain withdrawal

Intervention type: PROCEDURE
Intervention: Chest drain withdrawal

Intervention type: DEVICE
Intervention: Pain Monitor

Intervention type: DEVICE
Intervention: Pain Monitor
Study: NCT02014753

Intervention type: DEVICE
Intervention: cobalt-chromium everolimus-eluting stent (CoCr-EES)

Intervention type: DEVICE
Intervention: cobalt-chromium everolimus-eluting stent (CoCr-EES)
Study: NCT01672827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Flutemetamol
Description: No drug is administered in this intervention. These are scanned images being reviewed, previously acquired in various GE-067 studies.
Study: NCT01410331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JVS-100(4 mg) or placebo/8 injections
Description: 4 mg of JVS-100 or placebo delivered in 8 injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JVS-100(8 mg) or placebo/8 injections
Description: 8 mg of JVS-100 or placebo delivered in 8 injections
Study: NCT03649997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.
Study: NCT01410331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JVS-100(8 mg) or placebo/16 injections
Description: 8 mg of JVS-100 or placebo delivered in 16 injections
Study: NCT00729729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCA
Description: PO, 700mg, once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCA
Description: PO, 1000mg, once
Study: NCT00872859

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of Dermal Matrix substitute
Description: Dermal Matrix implanted in post mastectomy pts at time of mastectomy.
Study: NCT03603691

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Modified Manual Muscle Test
Description: Manual Muscle Testing Grading System from 0=No visible or palpable contraction to 5= full range of movement against gravity, maximal resistance

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Modified Manual Muscle Test
Description: Manual Muscle Testing Grading System from 0=No visible or palpable contraction to 5= full range of movement against gravity, maximal resistance

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Modified Manual Muscle Test
Description: Manual Muscle Testing Grading System from 0=No visible or palpable contraction to 5= full range of movement against gravity, maximal resistance
Study: NCT00545103

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered Once Daily (QD)
Study: NCT01953913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Patient will receive afatinib once daily
Study: NCT03649997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as oral suspension.
Study: NCT01410331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JVS-100(16 mg) or placebo/16 injections
Description: 16 mg of JVS-100 or placebo delivered in 16 injections
Study: NCT05243199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan
Description: The initial dose of 50mg Qd was increased to 50mg Bid after 1 week and maintained to 100mg Bid after 2 weeks if the patient could tolerate it (no follow-up exit criteria were found).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irbesartan
Description: The Initial dose of 75 mg Qd with sand, such as patients can tolerate and follow-up exit criteria (not appear, to 75 mg Bid to maintain after 1 week, 2 weeks can still be tolerance is raised to 150 mg Bid.
Study: NCT02394457

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosyntropin
Description: Intravenous Drug Infusion over 1 hour and a half

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural Blood Patch
Description: Blood drawn from subject and then same Blood placed into Epidural space by anesthesia personnel.
Study: NCT02778594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: nebicapone 50 mg tablets; oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: nebicapone 50 mg tablets; oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 3-202
Description: nebicapone 50 mg tablets; oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Nebicapone matching placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Nebicapone matching placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nebicapone matching placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa 100 mg / benserazide 25 mg
Description: Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) capsules; oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa 100 mg / benserazide 25 mg
Description: Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) capsules; oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa 100 mg / benserazide 25 mg
Description: Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) capsules; oral use

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levodopa 100 mg / benserazide 25 mg
Description: Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) capsules; oral use
Study: NCT04568265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1387
Description: Weekly intravenous infusion for 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1387
Description: Weekly intravenous infusion for 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-1387
Description: Weekly intravenous infusion for 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg
Description: Taken daily by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg
Description: Taken daily by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg
Description: Taken daily by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5 mg
Description: Taken daily by mouth
Study: NCT01688362

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP)
Description: Subjects in this group will receive 2 injections with PRP. Subjects will have will have 15cc of blood drawn with the Arthrex ACP syringe. The blood will be placed into the Arthrex PRP centrifuge and spun at 1500 rpms for 5 minutes. The platelets will be drawn off to create the PRP for injection. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the PRP solution using a 22g needle. A dry sterile dressing will be placed on the injection site. This injection will Take place at time zero and then two weeks later it will be repeated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later. For the first injection patients will have 15ml of blood drawn. This blood will then be discarded in a biohazard container. A 6ml solution of 4ml 0.25% Bupivacaine, 1ml 40mg Kenalog, and 1ml 4mg Dexamethasone will be prepared. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the steroid solution using a 22g needle. A dry sterile dressing will be placed at the injection site.~For the second injection two weeks later patients will have 15 ml of blood drawn. This blood will then be discarded in a biohazard container. Using the same technique as in Visit 2, the investigator will inject a 6 ml solution of 2 ml sterile normal saline with 4 ml 0.25% Bupivacaine to the shoulder using ultrasound. A dry sterile dressing will be placed at the injection site.
Study: NCT00298766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE
Description: Once weekly at: 0.7, 1.0, 1.3 or 1.6 mg/m2~Or~Twice-weekly at: 0.7, 1.0, or 1.3 mg/m2
Study: NCT05493579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implant supported overdenture
Description: Implant supported overdenture compared to complete denture
Study: NCT00581724

Intervention type: BEHAVIORAL
Intervention: Telephone interview or self report survey.
Description: We estimate that the completion time for the telephone interview or self-report survey will be 45-60 minutes.
Study: NCT04035356

Intervention type: DEVICE
Intervention: Aortic valve repair
Description: Use of a HAART Aortic Annuloplasty Device in patients undergoing aortic valve repair surgery

Intervention type: DEVICE
Intervention: Aortic valve repair
Description: Use of a HAART Aortic Annuloplasty Device in patients undergoing aortic valve repair surgery
Study: NCT03604094

Intervention type: PROCEDURE
Intervention: Ultrasonographic evaluation
Description: Right internal jugular vein will be evaluated with ultrasound for anatomical variations and dimensions

Intervention type: PROCEDURE
Intervention: Ultrasonographic evaluation
Description: Right internal jugular vein will be evaluated with ultrasound for anatomical variations and dimensions
Study: NCT04950491

Intervention type: OTHER
Group type: OTHER
Intervention: Modified Dental Anxiety Score (MDAS) questionnaire
Description: MDAS was used to measure the patients' anxiety toward dental treatment before implant surgery (Humphris, Dyer, \&Robinson, 2009). Originally, the MDAS questionnaire included five questions answered with a 5-category Likert scale. The original MDAS questionnaire does not cover anxiety toward implant surgery. Therefore, a question enquiring about patients' feelings towards implant surgery was added.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Dental Anxiety Score (MDAS) questionnaire
Description: MDAS was used to measure the patients' anxiety toward dental treatment before implant surgery (Humphris, Dyer, \&Robinson, 2009). Originally, the MDAS questionnaire included five questions answered with a 5-category Likert scale. The original MDAS questionnaire does not cover anxiety toward implant surgery. Therefore, a question enquiring about patients' feelings towards implant surgery was added.

Intervention type: OTHER
Group type: OTHER
Intervention: Pain questionnaire
Description: Patients were asked to describe the worst pain feeling using a standard 10 cm Visual Analog Scale (VAS) and the proportion of time spent in severe pain using a 5 category Likert scale. The number of analgesics taken per day was also asked.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain questionnaire
Description: Patients were asked to describe the worst pain feeling using a standard 10 cm Visual Analog Scale (VAS) and the proportion of time spent in severe pain using a 5 category Likert scale. The number of analgesics taken per day was also asked.

Intervention type: OTHER
Group type: OTHER
Intervention: Oral Health-Related Quality of Life (OHRQoL) questionnaire
Description: The OHRQoL comprises 14 questions covering problems the patient may in three main categories: oral function, daily activity, and post-operative symptoms (Chaushu, Becker, Zeltser, Vasker, \& Chaushu, 2004). Patients answered using a 5-category Likert scale.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Health-Related Quality of Life (OHRQoL) questionnaire
Description: The OHRQoL comprises 14 questions covering problems the patient may in three main categories: oral function, daily activity, and post-operative symptoms (Chaushu, Becker, Zeltser, Vasker, \& Chaushu, 2004). Patients answered using a 5-category Likert scale.
Study: NCT01496924

Intervention type: OTHER
Group type: OTHER
Intervention: speech therapy
Description: A single oral-motor technique will be used in a 10-times series intercalated with rest. Swallowing training techniques comprised indirect therapy (swallowing of saliva) and direct therapy (swallowing of food).
Study: NCT01434498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885 tablet
Description: GS-5885 tablet, 90 mg, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885 tablet
Description: GS-5885 tablet, 90 mg, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885 tablet
Description: GS-5885 tablet, 90 mg, QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9451 tablet
Description: GS-9451 tablet, 200 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9451 tablet
Description: GS-9451 tablet, 200 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9451 tablet
Description: GS-9451 tablet, 200 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tegobuvir capsule
Description: tegobuvir capsule, 30 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tegobuvir capsule
Description: tegobuvir capsule, 30 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin tablet
Description: ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin tablet
Description: ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo matching ribavirin tablet
Description: placebo matching ribavirin tablet, BID

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: placebo matching tegobuvir capsule
Description: placebo matching tegobuvir capsule, BID
Study: NCT02816255

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Full Face Mask with same CPAP Pressure
Description: Full Face Mask with same CPAP Pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Full Face Mask with new Pressure
Description: New cpap pressure derived from our formula for the final two weeks.
Study: NCT02695758

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine extended-release liposome injection
Study: NCT00508001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: ZD6474 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: ZD6474 100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: Placebo + Best Supportive Care
Study: NCT01591577

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lapatinib/Temozolomide/radiation
Description: Patients will be treated with a pulse dose of lapatinib every week and temozolomide 75 mg/m2 daily during radiation. Lapatinib will be administered beginning on the first day of radiation and temozolomide (+/-2 days). External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. Patients will have rest from temozolomide only for 2-4 weeks. Patients will continue with weekly pulse-dosing of lapatinib. After a 2-4 weeks rest(for temozolomide only) following completion of radiation therapy, temozolomide will be restarted as Cycle 1 at 150 mg/m2/day for 5 days out of every 28.Subsequent cycles can increase to 200 mg/m2/day as tolerated per investigator's judgment. Lapatinib pulse doses will be continued every week without interruption.Treatment will continue for 24 additional 28-day cycles of temozolomide if there is no evidence of progression.
Study: NCT04419558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Description: Sterile solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile solution for injection
Study: NCT01552408

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3 mg ranibizumab
Description: Cohort 1: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Description: Cohort 1: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted Pan Retinal Photocoagulation
Description: Cohort 2: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at V3 (Day 7) they will receive targeted pan retinal photocoagulation (PRP) based on ultra wide 200º field angiography. After the first session of PRP, subject's will have ultra wide 200º field angiography performed every 3 months to indicate areas of peripheral ischemia, which will be selectively treated at V9 (Month 6), V21 (Month 18), and V28 (Month 25), preserving areas of more perfused retina. This will minimize any visual field loss secondary to nonselective pan-retinal photocoagulation.
Study: NCT03162302

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.

Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.